Cancer Family
Carcinoma
CI-CAN-00000114Explore in graph →
7,369 active trials118 approved drugs1,149 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000114Explore in graph →
Clinical trials
25,729 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (3,405)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04148378 | A Pilot Study to Explore the Role of Gut Flora in Colorectal Cancer | withdrawn | — | 0 | ProgenaBiomeOTHER | 1 | Jun 5, 2025 | clinicaltrials |
| NCT06494046 | Defining Musical Toxicity and Its Effect on Patient Well-being | withdrawn | — | 0 | Mayo ClinicOTHER | 1 | Jun 4, 2025 | clinicaltrials |
| NCT06393751 |
| Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without Bevacizumab) in Patients With Recurrent Ovarian Cancer |
| withdrawn |
| Phase 1 / Phase 2 |
| 0 |
| National Cancer Institute (NCI)NIH |
| 0 |
| Jun 3, 2025 |
| clinicaltrials |
| NCT05840770 | Cemiplimab for the Treatment of Untreated Brain Metastases From PD-L1 >= 50% Non-Small Cell Lung Cancer | withdrawn | Phase 2 | 0 | City of Hope Medical CenterOTHER | 0 | May 26, 2025 | clinicaltrials |
| NCT05287347 | Panc CA Risk Model & Biomarker Testing In High-Risk Cohort | withdrawn | — | 0 | Beth Israel Deaconess Medical CenterOTHER | 1 | May 25, 2025 | clinicaltrials |
| NCT05672095 | Niraparib and Selenium for the Treatment of Recurrent BRCA Negative Platinum Resistant Ovarian Cancer | withdrawn | Phase 1 / Phase 2 | 0 | City of Hope Medical CenterOTHER | 0 | May 23, 2025 | clinicaltrials |
| NCT06361758 | Second-line Treatment With CAdonilimab and LEnvatinib for Unresectable HCC | withdrawn | Phase 2 | 0 | Shanghai Zhongshan HospitalOTHER | 1 | May 23, 2025 | clinicaltrials |
| NCT01125449 | Study of High Dose Intravenous (IV) Ascorbic Acid in Measurable Solid Tumor Disease | withdrawn | Phase 2 | 0 | Situs Cancer Research CenterOTHER | 1 | May 18, 2025 | clinicaltrials |
| NCT06145399 | A Study of 1 8F-FDHT PET/MRIScans in Women With Breast Cancer | withdrawn | Early Phase 1 | 0 | Memorial Sloan Kettering Cancer CenterOTHER | 0 | May 18, 2025 | clinicaltrials |
| NCT03877250 | Analysis of Biopsy Specimens to Study Responses to PD-1 or PD-L1 Therapies | withdrawn | — | 0 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 15, 2025 | clinicaltrials |
| NCT02756130 | Birinapant and Carboplatin in Treating Patients and Targeting Recurrent High Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (HGSOC) | withdrawn | Phase 1 / Phase 2 | 0 | Jonsson Comprehensive Cancer CenterOTHER | 1 | May 13, 2025 | clinicaltrials |
| NCT04329221 | Immunotherapy Before Transplantation for Skin Cancer Prevention in Organ Transplant Recipients | withdrawn | Phase 2 | 0 | Massachusetts General HospitalOTHER | 1 | May 7, 2025 | clinicaltrials |
| NCT04642287 | Immunotherapy After Transplantation for Skin Cancer Prevention in Organ Transplant Recipients | withdrawn | Phase 2 | 0 | Massachusetts General HospitalOTHER | 1 | May 7, 2025 | clinicaltrials |
| NCT02414100 | Patient Derived Cancer Cell Lines in Identifying Molecular Changes in Patients With Previously Untreated Pancreatic Cancer Receiving Gemcitabine Hydrochloride-Based Chemotherapy | withdrawn | — | 0 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | May 2, 2025 | clinicaltrials |
| NCT02671552 | Contrast-Enhanced Ultrasound in Predicting Treatment Response in Patients With Kidney Cancer Undergoing Cryosurgery | withdrawn | Early Phase 1 | 0 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | May 2, 2025 | clinicaltrials |
| NCT06644079 | Window of Opportunity Study of Topical Tranexamic Acid for Cutaneous Squamous Cell Carcinoma | withdrawn | Phase 2 | 0 | University of FloridaOTHER | 0 | May 2, 2025 | clinicaltrials |
| NCT03374852 | CPI-613 in Combination With Modified FOLFIRINOX in Patients With Locally Advanced Pancreatic Cancer | withdrawn | Phase 2 | 0 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 0 | Apr 29, 2025 | clinicaltrials |
| NCT04418219 | Breast Cancer Vaccine in Combination With Pembrolizumab for Treatment of Persistent, Recurrent, or Metastatic Breast Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Thomas Jefferson UniversityOTHER | 1 | Apr 29, 2025 | clinicaltrials |
| NCT02939807 | A Phase II Study of ABC294640 as Monotherapy in Patients With Advanced Hepatocellular Carcinoma | withdrawn | Phase 2 | 0 | Medical University of South CarolinaOTHER | 1 | Apr 27, 2025 | clinicaltrials |
| NCT04595981 | Chemo-embolization for Head and Neck Cancer | withdrawn | Phase 2 | 0 | University of Alabama at BirminghamOTHER | 1 | Apr 27, 2025 | clinicaltrials |
| NCT06522360 | Brigatinib Plus Chemotherapy or Local Consolidation Therapy in ALK Positive Advanced Non-small Cell Lung Cancer (BrightStar-2) | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Apr 24, 2025 | clinicaltrials |
| NCT03581500 | Hyperpolarized Carbon C 13 Pyruvate Magnetic Resonance Spectroscopic Imaging in Predicting Treatment Response in Patients With Prostate Cancer | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 23, 2025 | clinicaltrials |
| NCT04485026 | Local Consolidative Radiotherapy for Oligoprogressive in Non-small Cell Lung Carcinoma | withdrawn | Phase 2 | 0 | Wake Forest University Health SciencesOTHER | 0 | Apr 17, 2025 | clinicaltrials |
| NCT05648188 | A2R and Ectonucleotidases Expression in Lung Cancer Circulating Tumor Cells(LUNGadenosine) | withdrawn | — | 0 | Centre Hospitalier Universitaire de NiceOTHER | 1 | Apr 10, 2025 | clinicaltrials |
| NCT05940844 | Study of OB-002 in Patients With Refractory Metastatic Cancer | withdrawn | Phase 1 | 0 | Orion Biotechnology Polska Sp. z o.o.INDUSTRY | 0 | Apr 9, 2025 | clinicaltrials |
| NCT05608369 | Vorinostat in Combination With Chemoradiation in Locally Advanced HPV Negative HNSCC(HPV) | withdrawn | Phase 2 | 0 | Case Comprehensive Cancer CenterOTHER | 1 | Apr 4, 2025 | clinicaltrials |
| NCT06094842 | Autologous T Cells Lentivirally Transduced to Express L1CAM-Specific Chimeric Antigen Receptors in Treating Patients With Locally Advanced and Unresectable or Metastatic Small Cell Neuroendocrine Prostate Cancer | withdrawn | Phase 1 | 0 | Fred Hutchinson Cancer CenterOTHER | 1 | Apr 1, 2025 | clinicaltrials |
| NCT01345084 | Study Comparing Radiation Therapy and Chemotherapy With or Without Nimotuzumab(NICAP) | withdrawn | Phase 3 | 0 | Eurofarma Laboratorios S.A.INDUSTRY | 1 | Mar 28, 2025 | clinicaltrials |
| NCT05192850 | Endometrial Cancer Recurrence in Patients Taking Metformin | withdrawn | — | 0 | WellSpan HealthOTHER | 1 | Mar 28, 2025 | clinicaltrials |
| NCT03636607 | Diagnostic Significance of Single Center, Open and Prospective Evaluation of <Sup>18<Sup>F-FDG PET/CT Dynamic Imaging and Genomic Sequencing in Detecting Metastatic Lesions of Primary Hepatocellular Carcinoma | withdrawn | N/A | 0 | Fifth Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 1 | Mar 24, 2025 | clinicaltrials |
| NCT04889495 | A Post-marketing Surveillance to Assess the Safety and Effectiveness of Zirabev in Domestic Patients With Various Cancer | withdrawn | — | 0 | PfizerINDUSTRY | 0 | Mar 19, 2025 | clinicaltrials |
| NCT04976660 | TT-4 As a Single Agent in Subjects with Advanced Selected Solid Tumors | withdrawn | Phase 1 / Phase 2 | 0 | Tarus Therapeutics, Inc.INDUSTRY | 0 | Mar 18, 2025 | clinicaltrials |
| NCT05452408 | Antitumor-B KAC PK Study | withdrawn | Phase 1 | 0 | Medical College of WisconsinOTHER | 1 | Mar 18, 2025 | clinicaltrials |
| NCT06144827 | A Pilot Study For Patients Receiving Radiation Therapy for Liver Cancer(HepQuant) | withdrawn | N/A | 0 | Montefiore Medical CenterOTHER | 0 | Mar 18, 2025 | clinicaltrials |
| NCT04958967 | Phase Ib Study of FURMONERTINIB in Patients with NSCLC Having Exon 20 Insertion Mutation | withdrawn | Phase 1 | 0 | Allist Pharmaceuticals, Inc.INDUSTRY | 1 | Mar 14, 2025 | clinicaltrials |
| NCT05743270 | Study of RP3 in Combination With Nivolumab and Other Therapy in Patients With Locoregionally Advanced or Recurrent SCCHN | withdrawn | Phase 2 | 0 | Replimune, Inc.INDUSTRY | 8 | Mar 11, 2025 | clinicaltrials |
| NCT05714306 | PEP-DC and OC-DC Vaccine in High Grade Serous Ovarian Carcinoma(CHUV-OVACURE) | withdrawn | Phase 1 / Phase 2 | 0 | Centre Hospitalier Universitaire VaudoisOTHER | 0 | Mar 5, 2025 | clinicaltrials |
| NCT03169764 | QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy | withdrawn | Phase 1 / Phase 2 | 0 | ImmunityBio, Inc.INDUSTRY | 0 | Feb 24, 2025 | clinicaltrials |
| NCT03167164 | QUILT-3.045: NANT Merkel Cell Carcinoma (MCC) Vaccine: Combination Immunotherapy in Subjects With MCC Who Have Progressed on or After PD-L1 Therapy | withdrawn | Phase 1 / Phase 2 | 0 | ImmunityBio, Inc.INDUSTRY | 0 | Feb 21, 2025 | clinicaltrials |
| NCT03169738 | QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 Inhibitors | withdrawn | Phase 1 / Phase 2 | 0 | ImmunityBio, Inc.INDUSTRY | 0 | Feb 21, 2025 | clinicaltrials |
| NCT03175666 | QUILT-3.049: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Combination Immunotherapy in Subjects With TNBC Who Have Progressed on or After Anthracycline-based Chemotherapy | withdrawn | Phase 1 / Phase 2 | 0 | ImmunityBio, Inc.INDUSTRY | 0 | Feb 21, 2025 | clinicaltrials |
| NCT03197571 | QUILT-3.048: NANT Urothelial Cancer Vaccine: Combination Immunotherapy in Subjects With Urothelial Cancer Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy | withdrawn | Phase 1 / Phase 2 | 0 | ImmunityBio, Inc.INDUSTRY | 0 | Feb 21, 2025 | clinicaltrials |
| NCT03554109 | QUILT-3.057: NANT Neoadjuvant Triple- Negative Breast Cancer (TNBC) Vaccine(TNBC) | withdrawn | Phase 2 | 0 | ImmunityBio, Inc.INDUSTRY | 1 | Feb 21, 2025 | clinicaltrials |
| NCT03574649 | QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer | withdrawn | Phase 2 | 0 | ImmunityBio, Inc.INDUSTRY | 1 | Feb 21, 2025 | clinicaltrials |
| NCT06365918 | Study of VG2025 Delivered Intraperitoneally in Patients With Advanced Solid Tumors With Carcinomatosis | withdrawn | Phase 1 | 0 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 17, 2025 | clinicaltrials |
| NCT06199453 | The Evaluation of the Effectiveness, Safety and Tolerability of Treatment, Using a PSMA-Lu177, in Patients with ACC- an Open, Non-commercial Clinical Trial(LuRM_ACC/2023) | withdrawn | Phase 2 | 0 | Maria Sklodowska-Curie National Research Institute of OncologyOTHER | 1 | Feb 10, 2025 | clinicaltrials |
| NCT05296005 | Neoadjuvant Therapy for the Treatment of Gastroesophageal Junction and Gastric Cancers | withdrawn | Phase 1 | 0 | Ohio State University Comprehensive Cancer CenterOTHER | 0 | Feb 7, 2025 | clinicaltrials |
| NCT06075615 | A Study to Learn About Dacomitnib in Patients With Non-small Cell Lung Cancer Which Has Spread to the Brain. | withdrawn | — | 0 | PfizerINDUSTRY | 0 | Feb 7, 2025 | clinicaltrials |
| NCT06702384 | Molecular Analysis of Gastric and OEsophageal Cancers STudy(MAGnET) | withdrawn | — | 0 | Royal Marsden NHS Foundation TrustOTHER | 1 | Feb 6, 2025 | clinicaltrials |
| NCT05539365 | Dendritic Cell-Based Treatment Plus Immunotherapy for the Treatment of Metastatic or Unresectable Triple Negative Breast Cancer | withdrawn | Phase 2 | 0 | Roswell Park Cancer InstituteOTHER | 1 | Jan 29, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Jun 5, 2025source: clinicaltrials